Safety and effectiveness of the INVATEC MO.MA® proximal cerebral protection device during carotid artery stenting

Results from the ARMOUR pivotal trial

Gary M. Ansel, L. Nelson Hopkins, Michael R. Jaff, Paolo Rubino, J. Michael Bacharach, Dierk Scheinert, Subbarao Myla, Tony Das, Alberto Cremonesi, Richard Heuser, James Benenati, Horst Sievert, Bruce Gray, Rajesh Dave, Dariusz Dudek, Gary Roubin, Kenneth Rosenfield, James Margolis, Issam Moussa, Stephen Ramee & 6 others Gregory Mishkel, Robert Bersin, John Laird, Michael Dahn, Lowell Satler, Robert Safian

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Objective: The multicenter ARMOUR (ProximAl PRotection with the MO.MA Device DUring CaRotid Stenting) trial evaluated the 30-day safety and effectiveness of the MO.MA® Proximal Cerebral Protection Device (Invatec, Roncadelle, Italy) utilized to treat high surgical risk patients undergoing carotid artery stenting (CAS). Background: Distal embolic protection devices (EPD) have been traditionally utilized during CAS. The MO.MA device acts as a balloon occlusion "endovascular clamping" system to achieve cerebral protection prior to crossing the carotid stenosis. Methods: This prospective registry enrolled 262 subjects, 37 roll-in and 225 pivotal subjects evaluated with intention to treat (ITT) from September 2007 to February 2009. Subjects underwent CAS using the MO.MA device. The primary endpoint, myocardial infarction, stroke, or death through 30 days (30-day major adverse cardiac and cerebrovascular events [MACCE]) was compared to a performance goal of 13% derived from trials utilizing distal EPD. Results: For the ITT population, the mean age was 74.7 years with 66.7% of the cohort being male. Symptomatic patients comprised 15.1% and 28.9% were octogenarians. Device success was 98.2% and procedural success was 93.2%. The 30-day MACCE rate was 2.7% [95% CI (1.0-5.8%)] with a 30-day major stroke rate of 0.9%. No symptomatic patient suffered a stroke during this trial. Conclusions: The ARMOUR trial demonstrated that the MO.MA® Proximal Cerebral Protection Device is safe and effective for high surgical risk patients undergoing CAS. The absence of stroke in symptomatic patients is the lowest rate reported in any independently adjudicated prospective multicenter registry trial to date.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalCatheterization and Cardiovascular Interventions
Volume76
Issue number1
DOIs
StatePublished - Jul 1 2010

Fingerprint

Carotid Arteries
Safety
Equipment and Supplies
Embolic Protection Devices
Stroke
Registries
Balloon Occlusion
Carotid Stenosis
Constriction
Italy
Multicenter Studies
Myocardial Infarction
Population

Keywords

  • Carotid stenosis
  • Embolic protection
  • High surgical risk
  • Internal carotid artery
  • Peripheral vascular disease
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Safety and effectiveness of the INVATEC MO.MA® proximal cerebral protection device during carotid artery stenting : Results from the ARMOUR pivotal trial. / Ansel, Gary M.; Hopkins, L. Nelson; Jaff, Michael R.; Rubino, Paolo; Bacharach, J. Michael; Scheinert, Dierk; Myla, Subbarao; Das, Tony; Cremonesi, Alberto; Heuser, Richard; Benenati, James; Sievert, Horst; Gray, Bruce; Dave, Rajesh; Dudek, Dariusz; Roubin, Gary; Rosenfield, Kenneth; Margolis, James; Moussa, Issam; Ramee, Stephen; Mishkel, Gregory; Bersin, Robert; Laird, John; Dahn, Michael; Satler, Lowell; Safian, Robert.

In: Catheterization and Cardiovascular Interventions, Vol. 76, No. 1, 01.07.2010, p. 1-8.

Research output: Contribution to journalArticle

Ansel, GM, Hopkins, LN, Jaff, MR, Rubino, P, Bacharach, JM, Scheinert, D, Myla, S, Das, T, Cremonesi, A, Heuser, R, Benenati, J, Sievert, H, Gray, B, Dave, R, Dudek, D, Roubin, G, Rosenfield, K, Margolis, J, Moussa, I, Ramee, S, Mishkel, G, Bersin, R, Laird, J, Dahn, M, Satler, L & Safian, R 2010, 'Safety and effectiveness of the INVATEC MO.MA® proximal cerebral protection device during carotid artery stenting: Results from the ARMOUR pivotal trial', Catheterization and Cardiovascular Interventions, vol. 76, no. 1, pp. 1-8. https://doi.org/10.1002/ccd.22439
Ansel, Gary M. ; Hopkins, L. Nelson ; Jaff, Michael R. ; Rubino, Paolo ; Bacharach, J. Michael ; Scheinert, Dierk ; Myla, Subbarao ; Das, Tony ; Cremonesi, Alberto ; Heuser, Richard ; Benenati, James ; Sievert, Horst ; Gray, Bruce ; Dave, Rajesh ; Dudek, Dariusz ; Roubin, Gary ; Rosenfield, Kenneth ; Margolis, James ; Moussa, Issam ; Ramee, Stephen ; Mishkel, Gregory ; Bersin, Robert ; Laird, John ; Dahn, Michael ; Satler, Lowell ; Safian, Robert. / Safety and effectiveness of the INVATEC MO.MA® proximal cerebral protection device during carotid artery stenting : Results from the ARMOUR pivotal trial. In: Catheterization and Cardiovascular Interventions. 2010 ; Vol. 76, No. 1. pp. 1-8.
@article{ea51771272f74946981798abdccc6d6f,
title = "Safety and effectiveness of the INVATEC MO.MA{\circledR} proximal cerebral protection device during carotid artery stenting: Results from the ARMOUR pivotal trial",
abstract = "Objective: The multicenter ARMOUR (ProximAl PRotection with the MO.MA Device DUring CaRotid Stenting) trial evaluated the 30-day safety and effectiveness of the MO.MA{\circledR} Proximal Cerebral Protection Device (Invatec, Roncadelle, Italy) utilized to treat high surgical risk patients undergoing carotid artery stenting (CAS). Background: Distal embolic protection devices (EPD) have been traditionally utilized during CAS. The MO.MA device acts as a balloon occlusion {"}endovascular clamping{"} system to achieve cerebral protection prior to crossing the carotid stenosis. Methods: This prospective registry enrolled 262 subjects, 37 roll-in and 225 pivotal subjects evaluated with intention to treat (ITT) from September 2007 to February 2009. Subjects underwent CAS using the MO.MA device. The primary endpoint, myocardial infarction, stroke, or death through 30 days (30-day major adverse cardiac and cerebrovascular events [MACCE]) was compared to a performance goal of 13{\%} derived from trials utilizing distal EPD. Results: For the ITT population, the mean age was 74.7 years with 66.7{\%} of the cohort being male. Symptomatic patients comprised 15.1{\%} and 28.9{\%} were octogenarians. Device success was 98.2{\%} and procedural success was 93.2{\%}. The 30-day MACCE rate was 2.7{\%} [95{\%} CI (1.0-5.8{\%})] with a 30-day major stroke rate of 0.9{\%}. No symptomatic patient suffered a stroke during this trial. Conclusions: The ARMOUR trial demonstrated that the MO.MA{\circledR} Proximal Cerebral Protection Device is safe and effective for high surgical risk patients undergoing CAS. The absence of stroke in symptomatic patients is the lowest rate reported in any independently adjudicated prospective multicenter registry trial to date.",
keywords = "Carotid stenosis, Embolic protection, High surgical risk, Internal carotid artery, Peripheral vascular disease, Stroke",
author = "Ansel, {Gary M.} and Hopkins, {L. Nelson} and Jaff, {Michael R.} and Paolo Rubino and Bacharach, {J. Michael} and Dierk Scheinert and Subbarao Myla and Tony Das and Alberto Cremonesi and Richard Heuser and James Benenati and Horst Sievert and Bruce Gray and Rajesh Dave and Dariusz Dudek and Gary Roubin and Kenneth Rosenfield and James Margolis and Issam Moussa and Stephen Ramee and Gregory Mishkel and Robert Bersin and John Laird and Michael Dahn and Lowell Satler and Robert Safian",
year = "2010",
month = "7",
day = "1",
doi = "10.1002/ccd.22439",
language = "English (US)",
volume = "76",
pages = "1--8",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Safety and effectiveness of the INVATEC MO.MA® proximal cerebral protection device during carotid artery stenting

T2 - Results from the ARMOUR pivotal trial

AU - Ansel, Gary M.

AU - Hopkins, L. Nelson

AU - Jaff, Michael R.

AU - Rubino, Paolo

AU - Bacharach, J. Michael

AU - Scheinert, Dierk

AU - Myla, Subbarao

AU - Das, Tony

AU - Cremonesi, Alberto

AU - Heuser, Richard

AU - Benenati, James

AU - Sievert, Horst

AU - Gray, Bruce

AU - Dave, Rajesh

AU - Dudek, Dariusz

AU - Roubin, Gary

AU - Rosenfield, Kenneth

AU - Margolis, James

AU - Moussa, Issam

AU - Ramee, Stephen

AU - Mishkel, Gregory

AU - Bersin, Robert

AU - Laird, John

AU - Dahn, Michael

AU - Satler, Lowell

AU - Safian, Robert

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Objective: The multicenter ARMOUR (ProximAl PRotection with the MO.MA Device DUring CaRotid Stenting) trial evaluated the 30-day safety and effectiveness of the MO.MA® Proximal Cerebral Protection Device (Invatec, Roncadelle, Italy) utilized to treat high surgical risk patients undergoing carotid artery stenting (CAS). Background: Distal embolic protection devices (EPD) have been traditionally utilized during CAS. The MO.MA device acts as a balloon occlusion "endovascular clamping" system to achieve cerebral protection prior to crossing the carotid stenosis. Methods: This prospective registry enrolled 262 subjects, 37 roll-in and 225 pivotal subjects evaluated with intention to treat (ITT) from September 2007 to February 2009. Subjects underwent CAS using the MO.MA device. The primary endpoint, myocardial infarction, stroke, or death through 30 days (30-day major adverse cardiac and cerebrovascular events [MACCE]) was compared to a performance goal of 13% derived from trials utilizing distal EPD. Results: For the ITT population, the mean age was 74.7 years with 66.7% of the cohort being male. Symptomatic patients comprised 15.1% and 28.9% were octogenarians. Device success was 98.2% and procedural success was 93.2%. The 30-day MACCE rate was 2.7% [95% CI (1.0-5.8%)] with a 30-day major stroke rate of 0.9%. No symptomatic patient suffered a stroke during this trial. Conclusions: The ARMOUR trial demonstrated that the MO.MA® Proximal Cerebral Protection Device is safe and effective for high surgical risk patients undergoing CAS. The absence of stroke in symptomatic patients is the lowest rate reported in any independently adjudicated prospective multicenter registry trial to date.

AB - Objective: The multicenter ARMOUR (ProximAl PRotection with the MO.MA Device DUring CaRotid Stenting) trial evaluated the 30-day safety and effectiveness of the MO.MA® Proximal Cerebral Protection Device (Invatec, Roncadelle, Italy) utilized to treat high surgical risk patients undergoing carotid artery stenting (CAS). Background: Distal embolic protection devices (EPD) have been traditionally utilized during CAS. The MO.MA device acts as a balloon occlusion "endovascular clamping" system to achieve cerebral protection prior to crossing the carotid stenosis. Methods: This prospective registry enrolled 262 subjects, 37 roll-in and 225 pivotal subjects evaluated with intention to treat (ITT) from September 2007 to February 2009. Subjects underwent CAS using the MO.MA device. The primary endpoint, myocardial infarction, stroke, or death through 30 days (30-day major adverse cardiac and cerebrovascular events [MACCE]) was compared to a performance goal of 13% derived from trials utilizing distal EPD. Results: For the ITT population, the mean age was 74.7 years with 66.7% of the cohort being male. Symptomatic patients comprised 15.1% and 28.9% were octogenarians. Device success was 98.2% and procedural success was 93.2%. The 30-day MACCE rate was 2.7% [95% CI (1.0-5.8%)] with a 30-day major stroke rate of 0.9%. No symptomatic patient suffered a stroke during this trial. Conclusions: The ARMOUR trial demonstrated that the MO.MA® Proximal Cerebral Protection Device is safe and effective for high surgical risk patients undergoing CAS. The absence of stroke in symptomatic patients is the lowest rate reported in any independently adjudicated prospective multicenter registry trial to date.

KW - Carotid stenosis

KW - Embolic protection

KW - High surgical risk

KW - Internal carotid artery

KW - Peripheral vascular disease

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=77954255716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954255716&partnerID=8YFLogxK

U2 - 10.1002/ccd.22439

DO - 10.1002/ccd.22439

M3 - Article

VL - 76

SP - 1

EP - 8

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 1

ER -